Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
A phase 2 trial of Whole-body MRI in Prostate cancer, run by The European Uro-Oncology Group, completed.
Overview
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide is a phase 2 interventional study registered as NCT02815033 by The European Uro-Oncology Group, with 66 participants recorded, started 2015-07 and reaching its primary completion in 2020-06. Interventions recorded: Enzalutamide, 11C or 18F-Choline PET/CT, Whole body MRI, Bone scan. Conditions recorded: Prostate Cancer Metastatic.
Linked to the technology Whole-body MRI because the registry names it ("whole body mri") among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialPET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
Shares Whole-body MRI, Enzalutamide, Prostate cancer and the tag pipeline.
- TrialFOcal RECurrent Assessment and Salvage Treatment
Shares Whole-body MRI, Prostate cancer and the tag pipeline.
- TrialCombining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Shares Enzalutamide, Prostate cancer and the tag pipeline.
- TrialSafety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Shares Prostate cancer and the tag pipeline.
- TrialPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Shares Prostate cancer and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialEvaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
Shares Prostate cancer and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Prostate cancer and the tag pipeline.